IP Library Granted Patent US 8,697,122
Granted Patent B2
US 8,697,122 · App. 12/640,325 · Granted Apr 15, 2014

Formulation for retinoid-containing soft gelatin capsules

Inventors: Günter Ditzinger (Freiburg, DE); Bernhard Gabriel (Oberuzwil, CH); Anne-Hortense Schmitt-Hoffmann (Basel, CH); Lutz Wevelsiep (Lörrach, DE)
Assignee: Glaxo Group Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,697,122
App. No.
12/640,325
Granted
Apr 15, 2014
Kind
B2
Abstract

A new pharmaceutical formulation for retinoid-containing soft gelatin capsules is disclosed. The new formulation comprises a soft gelatin capsule filled with a fill mass comprising a retinoid as an active ingredient, a natural vegetable oil, a partially hydrogenated natural vegetable oil and medium chain triglycerides. Optionally, the new formulation also comprises a natural wax. In a particularly preferred embodiment, the soft gelatin capsule comprises pig gelatin in the capsule shell in combination with the above fill mass.

Claims (4)

1. A soft gelatin capsule comprising a shell filled with a fill mass comprising 20.00 mg of 9-cis-retinoic acid or pharmaceutically acceptable salts thereof as an active ingredient, 162.00 mg of soybean oil, 65.00 mg of partially hydrogenated soy bean oil, 23.00 mg of medium chain triglyceride selected from triglycerides of saturated fatty acids containing 8 to 10 carbon atoms, and 10.00 mg of natural wax wherein the soft gelatin shell is selected from the group consisting of

a) a capsule shell comprising 82 mg of pig gelatin, 22.3 mg of sorbitol, 16.5 mg of glycerol and 13.6 mg of water; and

b) a capsule shell comprising 82.0 mg of bovine gelatin, 15.3 mg of sorbitol, 26.4 mg of glycerol and 14.6 mg of water.

2. The soft gelatin capsule of claim 1 wherein said natural wax is yellow wax; said triglyceride is caprylic acid, capric acid, or a mixture of caprylic acid and capric acid; and additionally having an antioxidant selected from DL-α-tocopherol, butylhydroxy toluene (BHT) and butylhydroxy anisole (BHA).

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2020
From: BASILEA PHARMACEUTICA INTERNATIONAL LTD
To: GALEPHAR PHARMACEUTICAL RESEARCH, INC.
Reel/Frame 054358/0326 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2017
From: GLAXO GROUP LIMITED
To: BASILEA PHARMACEUTICA INTERNATIONAL LTD.
Reel/Frame 043414/0552 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2012
From: BASILEA PHARMACEUTICA INTERNATIONAL LTD
To: GLAXO GROUP LIMITED
Reel/Frame 029277/0193 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2010
From: DITZINGER, GUNTER; GABRIEL, BERNHARD; SCHMITT-HOFFMANN, ANNE-HORTENSE; WEVELSIEP, LUTZ
To: BASILEA PHARMACEUTICA AG
Reel/Frame 023926/0778 →
Priority Claims (1)
EP 03405788 · Nov 3, 2003 · regional
Continuity (2)
Continuation 10958704 · Oct 5, 2004
Related Publication 20100136108A1 · Jun 3, 2010